AxoGen, Inc. Appoints Amy Wendell to Board of Directors
19 September 2016 - 9:00PM
AxoGen, Inc. (NASDAQ:AXGN), a global leader in innovative surgical
solutions for peripheral nerve injuries, today announced the
election of Amy Wendell to its Board of Directors effective
September 16, 2016. Ms. Wendell was also appointed to the
Company’s Compensation and Governance Committees.
“Amy brings a wealth of proven healthcare
experience in market and technology development as well as
operating leadership,” commented Karen Zaderej, President and Chief
Executive Officer. “I am delighted Amy is joining the AxoGen
Board of Directors and look forward to her partnership as we
continue to develop the peripheral nerve repair market and AxoGen
products become the preeminent choice of surgeons.”
Most recently, Amy Wendell served as Covidien’s
Senior Vice President of Strategy and Business Development where
she led the company’s strategic planning and portfolio management
functions, including licensing, distribution and market
intelligence. Ms. Wendell joined Covidien, formerly known as
Tyco Healthcare/Kendall, in 1986 and she held roles of increasing
responsibility up through its acquisition by Medtronic (NYSE:MDT)
in January 2015. Since 2015, Ms. Wendell has been a Senior
Advisor for McKinsey’s Strategy and Corporate Finance Practice and
also serves as a member of McKinsey's Transactions Advisory
Board. Since January 2016, Ms. Wendell has also been a Senior
Advisor for Perella Weinberg Partners’ Healthcare Investment
Banking Practice. Ms. Wendell is also a member of the board
of directors of Ekso Bionics (NASDAQ:EKSO), and Por Cristo, a
non-profit organization. Ms. Wendell holds a Bachelor of
Science degree in Mechanical Engineering from Lawrence
Technological University and a Master of Science degree in
Biomedical Engineering from the University of Illinois.
“I am honored to join the AxoGen board at such
an exciting time in its history and I look forward to contributing
to the continued expansion of the business.” said Ms. Wendell.
“AxoGen has built an impressive team and has a tremendous
opportunity to drive greater awareness and improved solutions for
patients faced with potentially debilitating nerve injuries.”
Ms. Wendell has been elected to the board
following the resignation of Joe Mandato from the Company's board
of directors, which is also effective September 16, 2016.
"On behalf of our board of directors, I want
thank Joe for his 10 years of service and contributions to AxoGen,"
commented Ms. Zaderej. “Joe’s guidance - from AxoGen’s initial
funding to our current position of growth - has been invaluable in
helping AxoGen become a global leader in peripheral nerve
repair.”
About AxoGen, Inc.
AxoGen (AXGN) is a global leader in innovative surgical
solutions for peripheral nerve injuries. AxoGen’s portfolio of
products includes Avance® Nerve Graft, an off-the-shelf processed
human nerve allograft for bridging severed nerves without the
comorbidities associated with a second surgical site, AxoGuard®
Nerve Connector, a porcine submucosa extracellular matrix ("ECM")
coaptation aid for tensionless repair of severed nerves, and
AxoGuard® Nerve Protector, a porcine submucosa ECM product used to
wrap and protect injured peripheral nerves and reinforce the nerve
reconstruction while preventing soft tissue attachments. Along with
these core surgical products, AxoGen also offers AxoTouchTM
Two-Point Discriminator and AcroValTM Neurosensory & Motor
Testing System. These evaluation and measurement tools assist
healthcare professionals in detecting changes in sensation,
assessing return of sensory, grip and pinch function, evaluating
effective treatment interventions, and providing feedback to
patients on nerve function. The AxoGen portfolio of products is
available in the United States, Canada, the United Kingdom and
several European and international countries.
Cautionary Statements Concerning Forward-Looking StatementsThis
Press Release contains "forward-looking" statements as defined in
the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations or
predictions of future conditions, events or results based on
various assumptions and management's estimates of trends and
economic factors in the markets in which we are active, as well as
our business plans. Words such as "expects", "anticipates",
"intends", "plans", "believes", "seeks", "estimates", "projects",
"forecasts", "continue", "may", "should", "will" variations of such
words and similar expressions are intended to identify such
forward-looking statements. The forward-looking statements may
include, without limitation, statements regarding our growth, our
2016 guidance, product development, product potential, financial
performance, sales growth, product adoption, market awareness of
our products, data validation, our visibility at and sponsorship of
conferences and educational events. The forward-looking statements
are subject to risks and uncertainties, which may cause results to
differ materially from those set forth in the statements.
Forward-looking statements in this release should be evaluated
together with the many uncertainties that affect AxoGen's business
and its market, particularly those discussed in the risk factors
and cautionary statements in AxoGen's filings with the Securities
and Exchange Commission. Forward-looking statements are not
guarantees of future performance, and actual results may differ
materially from those projected. The forward-looking statements are
representative only as of the date they are made, and, except as
required by law, AxoGen assumes no responsibility to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact:
AxoGen, Inc.
Peter J. Mariani, Chief Financial Officer
386.462.6856
InvestorRelations@AxoGenInc.com
The Trout Group – Investor Relations
Brian Korb
646.378.2923
bkorb@troutgroup.com
Medtronic (NYSE:MDT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Oct 2023 to Oct 2024